These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38030835)

  • 1. A Chewing Study of Abuse-Deterrent Tablets Containing Polyethylene Oxide Using a Robotic Simulator.
    Chen B; Zhang F; Dhupia J; Morgenstern MP; Costello M; Boyce H; Sun WJ; Raofi S; Tian L; Xu W
    AAPS PharmSciTech; 2023 Nov; 24(8):245. PubMed ID: 38030835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Drug Release Testing to Evaluate the Retention of Abuse-Deterrent Properties of Polyethylene Oxide Matrix Tablets.
    Meruva S; Rezaei L; Thool P; Donovan MD
    AAPS PharmSciTech; 2020 Oct; 21(7):270. PubMed ID: 33025237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An in vitro approach for evaluating the oral abuse deterrence of solid oral extended-release opioids with properties intended to deter abuse via chewing.
    Externbrink A; Sharan S; Sun D; Jiang W; Keire D; Xu X
    Int J Pharm; 2019 Apr; 561():305-313. PubMed ID: 30862508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polyethylene Oxide (PEO) Molecular Weight Effects on Abuse-Deterrent Properties of Matrix Tablets.
    Meruva S; Donovan MD
    AAPS PharmSciTech; 2019 Dec; 21(1):28. PubMed ID: 31858320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vitro Assessment of Nasal Insufflation of Comminuted Drug Products Designed as Abuse Deterrent Using the Vertical Diffusion Cell.
    Boyce H; Smith D; Byrn S; Saluja B; Qu W; Gurvich VJ; Hoag SW
    AAPS PharmSciTech; 2018 May; 19(4):1744-1757. PubMed ID: 29582347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stability of Abuse-deterrent properties of PEO-based Abuse-deterrent formulation.
    Kibria G; Bandaranayake B; Zheng J; Lee S; Cruz C
    Int J Pharm; 2023 Jan; 631():122430. PubMed ID: 36493968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Drug-Polymer Interactions on Tablet Properties During the Development of Abuse-Deterrent Dosage Forms.
    Meruva S; Donovan MD
    AAPS PharmSciTech; 2019 Jan; 20(3):93. PubMed ID: 30690657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crush resistance and insufflation potential of poly(ethylene oxide)-based abuse deterrent formulations.
    Muppalaneni S; Mastropietro DJ; Omidian H
    Expert Opin Drug Deliv; 2016 Oct; 13(10):1375-82. PubMed ID: 27402156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of physical manipulation on in vitro and in vivo release profiles of oxycodone DETERx®: an extended-release, abuse-deterrent formulation.
    Kopecky EA; Fleming AB; Noonan PK; Varanasi RK; Grima M; Saim S; Mayock SP
    J Opioid Manag; 2014; 10(4):233-46. PubMed ID: 25162603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asymmetrical Flow Field Flow Fractionation for Molar Mass Characterization of Polyethylene Oxide in Abuse-Deterrent Formulations.
    Qu H; Smith WC; Feng X; Wang J; Pinto J; Xu X; Faustino PJ
    J Chromatogr A; 2023 Aug; 1705():464186. PubMed ID: 37453175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of tableting performance of Poly (ethylene oxide) in abuse-deterrent formulations using compaction simulation studies.
    Yu D; Seelam RR; Zhang F; Byrn SR; Hoag SW
    J Pharm Sci; 2021 Jul; 110(7):2789-2799. PubMed ID: 33737019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Manufacturing Process on the Retention of Abuse-Deterrent Properties of PEO-Matrix Tablets.
    Rezaei L; Meruva S; Donovan MD
    AAPS PharmSciTech; 2021 Dec; 23(1):38. PubMed ID: 34961912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physical Barrier Type Abuse-Deterrent Formulations: Mechanistic Understanding of Sintering-Induced Microstructural Changes in Polyethylene Oxide Placebo Tablets.
    Boyce HJ; Dave VS; Scoggins M; Gurvich VJ; Smith DT; Byrn SR; Hoag SW
    AAPS PharmSciTech; 2020 Jan; 21(3):86. PubMed ID: 31997096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanical Characterization of Thermally Annealed Tablets Containing Polyethylene Oxide for Abuse Deterrence.
    Tocce E; Bishop M; Balwinski K; Watson T; Lapham M; Hewlett K; Wontorcik A
    AAPS PharmSciTech; 2019 Nov; 21(1):2. PubMed ID: 31713019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preferential Oxycodone Loss of Physically Manipulated Abuse Deterrent Oxycodone HCl Extended Release Tablets Prepared for Nasal Insufflation Studies.
    Meng Z; Boyce HJ; Sun D; Kinjo M; Raofi S; Li T
    Pharm Res; 2021 Jul; 38(7):1263-1278. PubMed ID: 34128146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physical barrier type abuse-deterrent formulations: monitoring sintering-induced microstructural changes in polyethylene oxide placebo tablets by near infrared spectroscopy (NIRS).
    Boyce HJ; Ibrahim A; Hoag SW
    Drug Dev Ind Pharm; 2018 Nov; 44(11):1885-1894. PubMed ID: 30070152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro test methods for evaluating high molecular weight polyethylene oxide polymer induced hemolytic and thrombotic potential.
    Kim D; Natu R; Malinauskas R; Baek JH; Buehler PW; Feng X; Qu H; Pinto J; Xu X; Herbertson L
    Toxicol In Vitro; 2024 May; 97():105793. PubMed ID: 38401745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the impact of abuse deterring agents on the physicochemical factors of tramadol-loaded tablet and the definition of new abuse deterrent index.
    Won DG; Park G; Ngo HV; Jin G; Park C; Lee BJ
    Int J Pharm; 2021 Aug; 605():120726. PubMed ID: 34029664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abuse-deterrent features of an extended-release morphine drug product developed using a novel injection-molding technology for oral drug delivery.
    Skak N; Elhauge T; Dayno JM; Lindhardt K
    J Opioid Manag; 2017; 13(6):465-472. PubMed ID: 29308592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An index for evaluating difficulty of Chewing Index for chewable tablets.
    Gupta A; Chidambaram N; Khan MA
    Drug Dev Ind Pharm; 2015 Feb; 41(2):239-43. PubMed ID: 24252107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.